Alaric DeArment
Reporter
Latest From Alaric DeArment
Beckley Psytech Takes Another Step Toward Psychedelic Antidepressants
The private British biotech announced positive results from its Phase IIa study of BPL-003, which it said support its Phase IIb study of the same DMT-based drug.
Sellas Teases Biomarker-Driven Efficacy Of AML Drug With Phase IIa Results
The company remained tight-lipped on the biomarker driving high response rates for its CDK9 inhibitor SLS009 from a Phase II trial, as a Phase III interim analysis for its AML cancer vaccine galinpepimut-S draws near.
Ultomiris Now Carries All Four Soliris Indications, With NMOSD Approval
The approval follows a September rejection by the FDA related to the drug’s REMS, but an AstraZeneca exec told Scrip the company sees it as having a competitive advantage.
Third Time Is Not A Charm: KEYLYNK-006 Is Latest Keytruda/Lynparza Study To Fail
Merck said the Phase III study of the combination in non-small cell lung cancer did not meet its dual primary endpoint of overall survival and progression-free survival.
Orchard Will Launch Lenmeldy At Just Five Centers
Orchard, which Kyowa Kirin bought in October, gave Lenmeldy a $4.25m list price, exceeding the upper bound of about $3.9m set by ICER.
Seelos Aims For Conservative Approach After ALS Drug Shows Efficacy Signal
CEO Raj Mehta told Scrip Seelos anticipates conducting a Phase III study of SLS-005 after the cohort in HEALEY ALS failed overall, but indicated some efficacy in patients not receiving Relyvrio.